GlassScriptPhysician profile
Lien Duc Nguyen
NPI 1962443168
$828.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $157 · 2021: $209 · 2022: $17.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161.17 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.60 | 2019-2020 | |
| Medtronic, INC. | $121.60 | 2021 | |
| Glaxosmithkline, LLC. | $98.48 | 2019-2021 | |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.45 | 2019-2022 | |
| Boston Scientific Corporation | $52.63 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.92 | 2019-2020 | |
| Novo Nordisk INC | $30.03 | 2020 | |
| Allergan, INC. | $29.99 | 2020 | |
| Viiv Healthcare Company | $12.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2019 | |
| Pfizer INC. | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.